Show
Sort by
-
Development of a video-based deep learning model for differentiation of malignant and benign lesions during staging laparoscopy : is the machine better than the expert?
-
Mitoxantrone versus liposomal daunorubicin in induction of pediatric AML with risk stratification based on flow cytometry measurement of residual disease
-
Genomic determinants of patterns of failure in metachronous oligometastatic castration-sensitive prostate cancer
-
A phase 2 randomized open-label study of oral darolutamide monotherapy vs. androgen deprivation therapy in men with hormone-naive prostate cancer (EORTC-GUCG 1532)
-
Metabolic response rates of epcoritamab plus R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma : updated EPCORE NHL-2 data
-
Outcomes of childhood noninfant acute lymphoblastic leukemia with 11q23/KMT2A rearrangements in a modern therapy era : a retrospective international study
-
Evaluating the duration of response with mirvetuximab soravtansine for treating platinum-resistant ovarian cancer : reply
-
- Journal Article
- A1
- open access
Measurable residual disease and fusion partner independently predict survival and relapse risk in childhood KMT2A-rearranged acute myeloid leukemia : a study by the International Berlin-Frankfurt-Münster Study Group
-
- Journal Article
- A1
- open access
Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression : results from the SORAYA study
-
- Journal Article
- A1
- open access
Atezolizumab combined with bevacizumab and platinum-based therapy for platinum-sensitive ovarian cancer : placebo-controlled randomized phase III ATALANTE/ENGOT-ov29 trial